BR100 Increased By (0.27%)
BR30 Increased By (0.15%)
KSE100 Increased By (0.15%)
KSE30 Increased By (0.01%)
BECO 5.92 Decreased By ▼ -0.11 (-1.82%)
BML 57.31 Increased By ▲ 4.56 (8.64%)
BOP 34.09 Decreased By ▼ -0.16 (-0.47%)
CNERGY 8.20 Increased By ▲ 0.04 (0.49%)
DCL 12.15 Decreased By ▼ -0.19 (-1.54%)
FCCL 53.88 Decreased By ▼ -0.01 (-0.02%)
FCSC 5.25 Increased By ▲ 0.03 (0.57%)
FFL 18.01 Decreased By ▼ -0.02 (-0.11%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.23 Increased By ▲ 0.23 (2.09%)
KEL 8.17 Increased By ▲ 0.06 (0.74%)
KOSM 5.47 Increased By ▲ 0.09 (1.67%)
MLCF 88.79 Increased By ▲ 0.74 (0.84%)
NBP 186.50 Increased By ▲ 0.02 (0.01%)
PACE 10.96 Increased By ▲ 0.24 (2.24%)
PAEL 40.42 Increased By ▲ 0.48 (1.2%)
PIAHCLA 26.26 Increased By ▲ 0.09 (0.34%)
PIBTL 17.33 Increased By ▲ 0.01 (0.06%)
PPL 232.00 Decreased By ▼ -0.78 (-0.34%)
PRL 34.70 Decreased By ▼ -0.25 (-0.72%)
PTC 66.80 Decreased By ▼ -0.76 (-1.12%)
SEARL 91.45 Increased By ▲ 0.52 (0.57%)
SSGC 27.15 Decreased By ▼ -0.02 (-0.07%)
TELE 8.70 Increased By ▲ 0.13 (1.52%)
THCCL 65.35 Increased By ▲ 5.22 (8.68%)
TPLP 9.20 Increased By ▲ 0.44 (5.02%)
TREET 24.55 Increased By ▲ 0.01 (0.04%)
TRG 72.63 Increased By ▲ 0.88 (1.23%)
WAVES 10.70 Increased By ▲ 0.72 (7.21%)
WTL 1.26 No Change ▼ 0.00 (0%)
World

German panel to recommend J&J COVID vaccine for over-60s: Spiegel

  • Europe's drug regulator approved J&J's vaccine last month after examining cases of a rare blood clotting issue in US adults who received a dose. But it left it up to the European Union's member states to decide how to use it.
  • A spokeswoman for the Robert Koch Institute (RKI) for infectious diseases said the institute expects STIKO to make a recommendation on J&J's vaccine next week. She declined to comment further.
Published May 7, 2021 Updated May 7, 2021 06:06pm
By

BERLIN: Germany's vaccine committee, known as STIKO, plans to recommend Johnson & Johnson's COVID-19 vaccine only for people over the age of 60, German magazine Der Spiegel reported on Friday, citing no sources.

Europe's drug regulator approved J&J's vaccine last month after examining cases of a rare blood clotting issue in US adults who received a dose. But it left it up to the European Union's member states to decide how to use it.

A spokeswoman for the Robert Koch Institute (RKI) for infectious diseases said the institute expects STIKO to make a recommendation on J&J's vaccine next week. She declined to comment further.

Germany limited the shot from Anglo-Swedish drugmaker AstraZeneca to people over 60 after post-vaccination monitoring found rare - and sometimes fatal - cases of blood clotting, with younger women disproportionately affected.

Health Minister Jens Spahn announced on Thursday that Germany would make AstraZeneca available to all adults, regardless of age, to speed up its vaccination campaign.

The decision by the federal government follows moves by several German states to make AstraZeneca more widely available and comes as the pace of giving shots of mainstay vaccines from BioNTech/Pfizer and Moderna picks up.

Comments

Comments are closed for this article.